NASDAQ:CASC - Cascadian Therapeutics Stock Price, News, & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Sign in or create an account to add this stock to your watchlist. Get Started Previous Close$10.02Today's Range$10.02 - $10.0252-Week Range$3.18 - $10.21VolumeN/AAverage Volume1.09 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380. Receive CASC News and Ratings via Email Sign-up to receive the latest news and ratings for CASC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryBiotechnology SectorN/A Current SymbolNASDAQ:CASC Previous Symbol CUSIP68232410 CIK1412067 Webwww.cascadianrx.com Phone+1-206-8012100Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A Next Earnings DateN/A OptionableNot Optionable Cascadian Therapeutics (NASDAQ:CASC) Frequently Asked Questions What is Cascadian Therapeutics' stock symbol? Cascadian Therapeutics trades on the NASDAQ under the ticker symbol "CASC." How were Cascadian Therapeutics' earnings last quarter? Cascadian Therapeutics Inc (NASDAQ:CASC) released its quarterly earnings results on Wednesday, November, 8th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the Zacks' consensus estimate of ($0.29) by $0.01. During the same quarter in the prior year, the business posted ($0.09) earnings per share. View Cascadian Therapeutics' Earnings History. Has Cascadian Therapeutics been receiving favorable news coverage? Headlines about CASC stock have been trending somewhat negative on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Cascadian Therapeutics earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next several days. What other stocks do shareholders of Cascadian Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cascadian Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Athabasca Oil (ATH), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), NIC (EGOV), ALJ Regional (ALJJ), Transocean (RIG) and Gran Tierra Energy (GTE). Who are Cascadian Therapeutics' key executives? Cascadian Therapeutics' management team includes the folowing people: Christopher S. Henney Ph.D., Chairman of the Board (Age 76)Scott D. Myers, President, Chief Executive Officer, Director (Age 51)Julia Marie Eastland, Chief Financial Officer, Vice President - Corporate Development, Secretary (Age 51)Gary W. Christianson, Chief Operating Officer (Age 61)Scott Peterson Ph.D., Chief Scientific Officer (Age 54)Robert W. Azelby, Director (Age 49)Gwendolyn A. Fyfe M.D., Independent Director (Age 65)Steven P. James, Independent Director (Age 58)Ted W. Love M.D., Independent Director (Age 58)Daniel Keith Spiegelman, Independent Director (Age 58) What is Cascadian Therapeutics' official website? The official website for Cascadian Therapeutics is http://www.cascadianrx.com/. How can I contact Cascadian Therapeutics? Cascadian Therapeutics' mailing address is 3101 Western Ave Ste 600, SEATTLE, WA 98121-3047, United States. The biopharmaceutical company can be reached via phone at +1-206-8012100 or via email at [email protected] MarketBeat Community Rating for Cascadian Therapeutics (NASDAQ CASC)Community Ranking: 2.4 out of 5 ( )Outperform Votes: 264 (Vote Outperform)Underperform Votes: 279 (Vote Underperform)Total Votes: 543MarketBeat's community ratings are surveys of what our community members think about Cascadian Therapeutics and other stocks. Vote "Outperform" if you believe CASC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CASC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/20/2019 by MarketBeat.com StaffFeatured Article: Closed-End Mutual Funds Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.